Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 7/2017

01-07-2017 | Review

Novel Biomarkers for Pancreatic Cysts

Authors: Harkirat Singh, Kevin McGrath, Aatur D. Singhi

Published in: Digestive Diseases and Sciences | Issue 7/2017

Login to get access

Abstract

With increased utilization and ongoing advancements in cross-sectional abdominal imaging, the identification of a pancreatic cyst has become a frequent finding. While many pancreatic cysts are associated with a benign clinical course, others may transform into pancreatic ductal adenocarcinoma. However, distinguishing a benign from a malignant pancreatic cyst or pancreatic cyst with malignant potential on the basis of standard clinical findings, imaging parameters and ancillary studies can be challenging. Hence, a significant interest within the past decade has been the identification of novel biomarkers to accurately classify and prognosticate a pancreatic cyst. Within this review, we discuss novel DNA, miRNA, protein and metabolite biomarkers, and their relevance in clinical practice. In addition, we focus on future areas of research that have the potential to change pancreatic cyst management.
Literature
1.
2.
Lee KS, Sekhar A, Rofsky NM, Pedrosa I. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol. 2010;105:2079–2084.CrossRefPubMed
3.
de Jong K, Nio CY, Hermans JJ, Dijkgraaf MG, et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol. 2010;8:806–811.CrossRefPubMed
4.
Pitman MB, Centeno BA, Ali SZ, Genevay M, et al. Standardized terminology and nomenclature for pancreatobiliary cytology: the Papanicolaou Society of Cytopathology guidelines. Diagn Cytopathol. 2014;42:338–350.CrossRefPubMed
5.
6.
7.
Sohn TA, Yeo CJ, Cameron JL, Hruban RH, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239:788–797. (discussion 797-789).CrossRefPubMedPubMedCentral
8.
Yachida S, Jones S, Bozic I, Antal T, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114–1117.CrossRefPubMedPubMedCentral
9.
Salvia R, Fernandez-del Castillo C, Bassi C, Thayer SP, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239:678–685. (discussion 685-677).CrossRefPubMedPubMedCentral
10.
Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32.CrossRefPubMed
11.
Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197.CrossRefPubMed
12.
Pelaez-Luna M, Chari ST, Smyrk TC, Takahashi N, et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol. 2007;102:1759–1764.CrossRefPubMed
13.
Tang RS, Weinberg B, Dawson DW, Reber H, et al. Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol. 2008;6:815–819. (quiz 719).CrossRefPubMed
14.
Nagai K, Doi R, Ito T, Kida A, et al. Single-institution validation of the International Consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg. 2009;16:8.CrossRef
15.
Goh BK, Tan DM, Ho MM, Lim TK, et al. Utility of the Sendai Consensus guidelines for branch-duct intraductal papillary mucinous neoplasms: a systematic review. J Gastrointest Surg. 2014;18:1350–1357.CrossRefPubMed
16.
Kaimakliotis P, Riff B, Pourmand K, Chandrasekhara V, et al. Sendai and Fukuoka Consensus guidelines identify advanced neoplasia in patients with suspected mucinous cystic neoplasms of the pancreas. Clin Gastroenterol Hepatol. 2015;13:1808–1815.CrossRefPubMed
17.
Hsiao CY, Yang CY, Wu JM, Kuo TC, Tien YM. Utility of the 2006 Sendai and 2012 Fukuoka guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas: a single-center experience with 138 surgically treated patients. Medicine (Baltimore). 2016;95:e4922.CrossRef
18.
Scheiman JM, Hwang JH, Moayyedi P. American Gastroenterological Association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:824–848.e822.CrossRefPubMed
19.
Buscaglia JM, Giday SA, Kantsevoy SV, Jagannath SB, et al. Patient- and cyst-related factors for improved prediction of malignancy within cystic lesions of the pancreas. Pancreatology. 2009;9:631–638.CrossRefPubMed
20.
Correa-Gallego C, Ferrone CR, Thayer SP, Wargo JA, et al. Incidental pancreatic cysts: do we really know what we are watching? Pancreatology. 2010;10:144–150.CrossRefPubMedPubMedCentral
21.
de Jong K, Nio CY, Mearadji B, Phoa SS, et al. Disappointing interobserver agreement among radiologists for a classifying diagnosis of pancreatic cysts using magnetic resonance imaging. Pancreas. 2012;41:278–282.CrossRefPubMed
22.
Cho CS, Russ AJ, Loeffler AG, Rettammel RJ, et al. Preoperative classification of pancreatic cystic neoplasms: the clinical significance of diagnostic inaccuracy. Ann Surg Oncol. 2013;20:3112–3119.CrossRefPubMedPubMedCentral
23.
Jones MJ, Buchanan AS, Neal CP, Dennison AR, et al. Imaging of indeterminate pancreatic cystic lesions: a systematic review. Pancreatology. 2013;13:436–442.CrossRefPubMed
24.
25.
Salvia R, Malleo G, Marchegiani G, Pennacchio S, et al. Pancreatic resections for cystic neoplasms: from the surgeon’s presumption to the pathologist’s reality. Surgery. 2012;152:S135–S142.CrossRefPubMed
26.
Suzuki R, Thosani N, Annangi S, Guha S, Bhutani MS. Diagnostic yield of EUS-FNA-based cytology distinguishing malignant and benign IPMNs: a systematic review and meta-analysis. Pancreatology. 2014;14:380–384.CrossRefPubMed
27.
Thosani N, Thosani S, Qiao W, Fleming JB, et al. Role of EUS-FNA-based cytology in the diagnosis of mucinous pancreatic cystic lesions: a systematic review and meta-analysis. Dig Dis Sci. 2010;55:2756–2766.CrossRefPubMedPubMedCentral
28.
Goh BK, Tan DM, Thng CH, Lee SY, et al. Are the Sendai and Fukuoka Consensus guidelines for cystic mucinous neoplasms of the pancreas useful in the initial triage of all suspected pancreatic cystic neoplasms? A single-institution experience with 317 surgically-treated patients. Ann Surg Oncol. 2014;21:1919–1926.CrossRefPubMed
29.
Sahora K, Mino-Kenudson M, Brugge W, Thayer SP, et al. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg. 2013;258:466–475.CrossRefPubMed
30.
Goh BK, Lin Z, Tan DM, Thng CH, et al. Evaluation of the Fukuoka Consensus guidelines for intraductal papillary mucinous neoplasms of the pancreas: results from a systematic review of 1,382 surgically resected patients. Surgery. 2015;158:1192–1202.CrossRefPubMed
31.
Ahmad NA, Kochman ML, Brensinger C, Brugge WR, et al. Interobserver agreement among endosonographers for the diagnosis of neoplastic versus non-neoplastic pancreatic cystic lesions. Gastrointest Endosc. 2003;58:59–64.CrossRefPubMed
32.
Pitman MB, Lewandrowski K, Shen J, Sahani D, et al. Pancreatic cysts: preoperative diagnosis and clinical management. Cancer Cytopathol. 2010;118:1–13.CrossRefPubMed
33.
Khalid A, Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol. 2007;102:2339–2349.CrossRefPubMed
34.
Maker AV, Lee LS, Raut CP, Clancy TE, Swanson RS. Cytology from pancreatic cysts has marginal utility in surgical decision-making. Ann Surg Oncol. 2008;15:3187–3192.CrossRefPubMed
35.
Vege SS, Ziring B, Jain R, Moayyedi P. American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–822. (quize812-813).CrossRefPubMed
36.
Singhi AD, Zeh HJ, Brand RE, Nikiforova MN, et al. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data. Gastrointest Endosc. 2016;83:e1102.
37.
Ma GK, Goldberg DS, Thiruvengadam N, Chandrasekhara V, et al. Comparing American Gastroenterological Association pancreatic cyst management guidelines with Fukuoka Consensus guidelines as predictors of advanced neoplasia in patients with suspected pancreatic cystic neoplasms. J Am Coll Surg. 2016;223:e721.CrossRef
38.
Fernandez-Del Castillo C, Tanaka M. Management of pancreatic cysts: the evidence is not here yet. Gastroenterology. 2015;148:685–687.CrossRefPubMed
39.
Lennon AM, Ahuja N, Wolfgang CL. AGA guidelines for the management of pancreatic cysts. Gastroenterology. 2015;149:825.CrossRefPubMed
40.
Canto MI, Hruban RH. Managing pancreatic cysts: less is more? Gastroenterology. 2015;148:688–691.CrossRefPubMed
41.
Bailey P, Chang DK, Nones K, Johns AL, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.CrossRefPubMed
42.
Jones S, Zhang X, Parsons DW, Lin JC, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–1806.CrossRefPubMedPubMedCentral
43.
Khalid A, McGrath KM, Zahid M, Wilson M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol. 2005;3:967–973.CrossRefPubMed
44.
Khalid A, Zahid M, Finkelstein SD, LeBlanc JK, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc. 2009;69:1095–1102.CrossRefPubMed
45.
Shen J, Brugge WR, Dimaio CJ, Pitman MB. Molecular analysis of pancreatic cyst fluid: a comparative analysis with current practice of diagnosis. Cancer. 2009;117:217–227.PubMed
46.
Sreenarasimhaiah J, Lara LF, Jazrawi SF, Barnett CC, Tang SJ. A comparative analysis of pancreas cyst fluid CEA and histology with DNA mutational analysis in the detection of mucin producing or malignant cysts. JOP. 2009;10:163–168.PubMed
47.
Panarelli NC, Sela R, Schreiner AM, Crapanzano JP, et al. Commercial molecular panels are of limited utility in the classification of pancreatic cystic lesions. Am J Surg Pathol. 2012;36:1434–1443.CrossRefPubMed
48.
Toll AD, Kowalski T, Loren D, Bibbo M. The added value of molecular testing in small pancreatic cysts. JOP. 2010;11:582–586.PubMed
49.
Wu J, Matthaei H, Maitra A, Dal Molin M, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3:a66.CrossRef
50.
Furukawa T, Kuboki Y, Tanji E, Yoshida S, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep. 2011;1:161.CrossRefPubMedPubMedCentral
51.
Singhi AD, Nikiforova MN, Fasanella KE, McGrath KM, et al. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin Cancer Res. 2014;20:4381–4389.CrossRefPubMed
52.
Wu J, Jiao Y, Dal Molin M, Maitra A, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA. 2011;108:21188–21193.CrossRefPubMedPubMedCentral
53.
Lee JH, Kim Y, Choi JW, Kim YS. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Springerplus. 2016;5:1172.CrossRefPubMedPubMedCentral
54.
Springer S, Wang Y, Dal Molin M, Masica DL, et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology. 2015;149:1501–1510.CrossRefPubMedPubMedCentral
55.
Amato E, Molin MD, Mafficini A, Yu J, et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol. 2014;233:217–227.CrossRefPubMedPubMedCentral
56.
Biankin AV, Biankin SA, Kench JG, Morey AL, et al. Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut. 2002;50:861–868.CrossRefPubMedPubMedCentral
57.
58.
Sasaki S, Yamamoto H, Kaneto H, Ozeki I, et al. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas. Oncol Rep. 2003;10:21–25.PubMed
59.
Rosenbaum MW, Jones M, Dudley JC, et al. Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts. Cancer Cytopathol. 2017;125:41–47.CrossRef
60.
Kanda M, Matthaei H, Wu J, Hong SM, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142:e739.CrossRef
61.
Kanda M, Sadakari Y, Borges M, Topazian M, et al. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol. 2013;11:e715.CrossRef
62.
Pea A, Yu J, Rezaee N, et al. Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg. 2016. doi:10.​1097/​SLA.​0000000000001817​.
63.
Jimenez RE, Warshaw AL, Z’Graggen K, Hartwig W, et al. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg. 1999;230:501–509. (discussion 509-511).CrossRefPubMedPubMedCentral
64.
Jones M, Zheng Z, Wang J, Dudley J, et al. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. Gastrointest Endosc. 2016;83:140–148.CrossRefPubMed
65.
Yeh TS, Cheng AJ, Chen TC, Jan YY, et al. Telomerase activity is a useful marker to distinguish malignant pancreatic cystic tumors from benign neoplasms and pseudocysts. J Surg Res. 1999;87:171–177.CrossRefPubMed
66.
Hata T, Dal Molin M, Suenaga M, Yu J, et al. Cyst fluid telomerase activity predicts the histologic grade of cystic neoplasms of the pancreas. Clin Cancer Res. 2016;22:5141–5151.CrossRefPubMed
67.
D’Angelo B, Benedetti E, Cimini A, Giordano A. MicroRNAs: a puzzling tool in cancer diagnostics and therapy. Anticancer Res. 2016;36:5571–5575.CrossRefPubMed
68.
Sethi A, Sholl LM. Emerging evidence for MicroRNAs as regulators of cancer stem cells. Cancers (Basel). 2011;3:3957–3971.CrossRef
69.
70.
Liu A, Tetzlaff MT, Vanbelle P, Elder D, et al. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol. 2009;2:519–527.PubMedPubMedCentral
71.
Bloomston M, Frankel WL, Petrocca F, Volinia S, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901–1908.CrossRefPubMed
72.
Yu J, Li A, Hong SM, Hruban RH, Goggins M. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res. 2012;18:981–992.CrossRefPubMed
73.
Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 2009;8:340–346.CrossRefPubMedPubMedCentral
74.
Ryu JK, Matthaei H, Dal Molin M, Hong SM, et al. Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology. 2011;11:343–350.CrossRefPubMedPubMedCentral
75.
Caponi S, Funel N, Frampton AE, Mosca F, et al. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann Oncol. 2013;24:734–741.CrossRefPubMed
76.
Farrell JJ, Toste P, Wu N, Li L, et al. Endoscopically acquired pancreatic cyst fluid microRNA 21 and 221 are associated with invasive cancer. Am J Gastroenterol. 2013;108:1352–1359.CrossRefPubMed
77.
Matthaei H, Wylie D, Lloyd MB, Dal Molin M, et al. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res. 2012;18:4713–4724.CrossRefPubMedPubMedCentral
78.
Henry JC, Bassi C, Giovinazzo F, Bloomston M. MicroRNA from pancreatic duct aspirate differentiates cystic lesions of the pancreas. Ann Surg Oncol. 2013;20:S661–S666.CrossRefPubMed
79.
Lubezky N, Loewenstein S, Ben-Haim M, Brazowski E, et al. MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2013;153:663–672.CrossRefPubMed
80.
Lee LS, Szafranska-Schwarzbach AE, Wylie D, Doyle LA, et al. Investigating MicroRNA expression profiles in pancreatic cystic neoplasms. Clin Transl Gastroenterol. 2014;5:e47.CrossRefPubMedPubMedCentral
81.
Permuth-Wey J, Chen YA, Fisher K, McCarthy S, et al. A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas. PLoS ONE. 2015;10:e0116869.CrossRefPubMedPubMedCentral
82.
Wang J, Paris PL, Chen J, Ngo V, et al. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions. Cancer Lett. 2015;356:404–409.CrossRefPubMed
83.
Yonezawa S, Higashi M, Yamada N, Yokoyama S, Goto M. Significance of mucin expression in pancreatobiliary neoplasms. J Hepatobiliary Pancreat Sci. 2010;17:108–124.CrossRefPubMed
84.
Moschovis D, Bamias G, Delladetsima I. Mucins in neoplasms of pancreas, ampulla of Vater and biliary system. World J Gastrointest Oncol. 2016;8:725–734.CrossRefPubMedPubMedCentral
85.
Carrara S, Cangi MG, Arcidiacono PG, Perri F, et al. Mucin expression pattern in pancreatic diseases: findings from EUS-guided fine-needle aspiration biopsies. Am J Gastroenterol. 2011;106:1359–1363.CrossRefPubMed
86.
Haab BB, Porter A, Yue T, Li L, et al. Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg. 2010;251:937–945.CrossRefPubMedPubMedCentral
87.
Cao Z, Maupin K, Curnutte B, Fallon B, et al. Specific glycoforms of MUC5AC and endorepellin accurately distinguish mucinous from nonmucinous pancreatic cysts. Mol Cell Proteomics. 2013;12:2724–2734.CrossRefPubMedPubMedCentral
88.
Maker AV, Katabi N, Gonen M, DeMatteo RP, et al. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol. 2011;18:199–206.CrossRefPubMed
89.
Jabbar KS, Verbeke C, Hyltander AG, Sjovall H, et al. Proteomic mucin profiling for the identification of cystic precursors of pancreatic cancer. J Natl Cancer Inst. 2014;106:9.CrossRef
90.
Maker AV, Katabi N, Qin LX, Klimstra DS, et al. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2011;17:1502–1508.CrossRefPubMedPubMedCentral
91.
Schmidt CM, Yip-Schneider MT, Ralstin MC, Wentz S, et al. PGE(2) in pancreatic cyst fluid helps differentiate IPMN from MCN and predict IPMN dysplasia. J Gastrointest Surg. 2008;12:243–249.CrossRefPubMed
92.
Lee LS, Banks PA, Bellizzi AM, Sainani NI, et al. Inflammatory protein profiling of pancreatic cyst fluid using EUS-FNA in tandem with cytokine microarray differentiates between branch duct IPMN and inflammatory cysts. J Immunol Methods. 2012;382:142–149.CrossRefPubMedPubMedCentral
93.
Allen PJ, Qin LX, Tang L, Klimstra D, et al. Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm. Ann Surg. 2009;250:754–760.CrossRefPubMedPubMedCentral
94.
Park J, Yun HS, Lee KH, Lee KT, et al. Discovery and validation of biomarkers that distinguish mucinous and nonmucinous pancreatic cysts. Cancer Res. 2015;75:3227–3235.CrossRefPubMed
95.
Kelly KA, Bardeesy N, Anbazhagan R, Gurumurthy S, et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 2008;5:e85.CrossRefPubMedPubMedCentral
96.
Bausch D, Mino-Kenudson M, Fernandez-Del Castillo C, Warshaw AL, et al. Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms. J Gastrointest Surg. 2009;13:1948–1954. (discussion 1954).CrossRefPubMedPubMedCentral
97.
98.
Raty S, Sand J, Laukkarinen J, Vasama K, et al. Cyst fluid SPINK1 may help to differentiate benign and potentially malignant cystic pancreatic lesions. Pancreatology. 2013;13:530–533.CrossRefPubMed
99.
Das KK, Xiao H, Geng X, Fernandez-Del-Castillo C, et al. mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN). Gut. 2014;63:1626–1634.PubMed
100.
Park WG, Wu M, Bowen R, Zheng M, et al. Metabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenine. Gastrointest Endosc. 2013;78:e292.
101.
Zikos T, Pham K, Bowen R, Chen AM, et al. Cyst fluid glucose is rapidly feasible and accurate in diagnosing mucinous pancreatic cysts. Am J Gastroenterol. 2015;110:909–914.CrossRefPubMed
Metadata
Title
Novel Biomarkers for Pancreatic Cysts
Authors
Harkirat Singh
Kevin McGrath
Aatur D. Singhi
Publication date
01-07-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4491-4

Other articles of this Issue 7/2017

Digestive Diseases and Sciences 7/2017 Go to the issue

Review

Surgical Approaches to Chronic Pancreatitis: Indications and Techniques

Review

Autoimmune Pancreatitis

Review

Genetic Risk in Chronic Pancreatitis: The Trypsin-Dependent Pathway

Review

Pancreatic Cysts and Guidelines

Review

Natural History of Pancreatic Cysts

Review

Imaging Pancreatic Cysts with CT and MRI
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits